Harrow Q3 2026 slides: record revenue, product portfolio expansion
Harrow (HROW) reported Q3 2026 revenue of $99.3M, up 41% sequentially and 39% YoY, with adjusted EBITDA at $21.2M. Key products VEVYE, IHEEZO, and TRIESENCE drove growth. The company reaffirmed FY 2026 revenue guidance of $350M-$365M but lowered adjusted EBITDA outlook. Harrow expanded its product portfolio and commercial infrastructure, acquiring TYRVAYA in October 2026.
How this was made
The 30-second read
Why it matters
Earnings beat and guidance update drove a strong pre‑market rally, but lower EBITDA outlook introduces downside risk.
Market read
First‑report earnings with material numbers; likely to influence trading in the ophthalmic biotech niche.
What to watch
Integration risk of recent TYRVAYA acquisition and reliance on a few key products.
Background
Harrow presented Q3 2026 results, noting record revenue, product mix shift to branded items, and a recent acquisition.
Ticker impact
Q3 2026 earnings released with record $99.3M revenue and revised EBITDA guidance, causing a >20% pre‑market price jump.
upward pressure as market prices in record revenue and product momentum
First‑report earnings numbers and guidance change are material; the stock already moved >20% pre‑market.
Market effects
Highlights growth potential in ophthalmology drug space, may lift peers with similar dry‑eye products.
Positive for US biotech sector, especially ophthalmic specialty firms.
Limited to niche biotech segment; no broad market effect.
Counterpoint
EBITDA guidance cut could signal margin pressure; investors may wait for Q4 results before adding.
Key entities
- companyHarrow
NASDAQ‑listed ophthalmology firm reporting Q3 results.
